Narrative synthesis of case report literature
Priapism Risk with Trazodone: What Case Report Data Tells Us
How the well-documented but rare risk of priapism with trazodone came to be understood, and what the case report literature suggests about risk factors.
Published August 8, 2026. Reviewed by our editorial team on August 8, 2026.
Who was studied: Men prescribed trazodone, based on published case reports and case series
Priapism is one of trazodone's most specifically discussed rare risks, and much of what is known about it in the medical literature comes from published case reports and case series accumulated over the decades since trazodone's approval — the type of evidence that first identified this risk and led to its inclusion in FDA labeling.
These case reports describe priapism occurring across a range of trazodone doses, including doses used for off-label insomnia treatment, not exclusively at high antidepressant doses. Certain underlying conditions, including sickle cell disease and anatomical factors such as Peyronie's disease, are described in this literature and in FDA labeling as potentially raising baseline risk, which is why disclosing these conditions to a prescriber matters.
Main result: Trazodone-associated priapism is described in the published case report literature as rare but well-documented, occurring across a range of doses, with certain conditions — including sickle cell disease, and anatomical factors like Peyronie's disease — described in case reports as raising baseline risk, consistent with current FDA labeling.
Limitations: Case reports can establish that an association exists and describe patterns, but cannot by themselves establish a precise incidence rate the way a large prospective study could — this is a known general limitation of case-report-based safety literature, not specific to trazodone.
Not medical advice. This summary is educational and does not replace individualized guidance from your prescriber.
